The oversubscribed round also includes participation by Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures. The company will use the funds to meet growing consumer demand, spearhead retail expansion, and drive continued research and development in a new sector, including bringing new genetically engineered probiotic products to market that address the unique and newly arising biological challenges of modern living.

ZBiotics is the world's first maker of genetically engineered probiotics, purpose-built to improve our health, starting with helping our bodies handle the unique and newly arising biological challenges of modern living. Developed by CEO and co-founder Zack Abbott, Ph.D., the company's flagship product breaks down acetaldehyde, an unwanted byproduct of alcohol associated with the day-after effects of drinking. ZBiotics makes products for consumers who want to live healthier lives and take a more active role in their well-being. A bioengineering company, ZBiotics employs the power of engineered probiotics to bring new functionality to the human body or to augment existing functions. It's a new kind of genetic engineering: transparent, responsible, and built directly for consumers.